BRIEF published on 11/13/2025 at 10:12, 1 day 5 hours ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 1 day 5 hours ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 7 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 7 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 22 days 2 hours ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
PRESS RELEASE published on 10/23/2025 at 13:16, 22 days 2 hours ago Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025 Biotest AG cancels extraordinary general meeting scheduled for 28 October 2025 following withdrawal of convocation request by Grifols S.A Grifols S.A. Cancellation Extraordinary General Meeting Biotest AG Legal Form Change
BRIEF published on 10/09/2025 at 17:35, 1 month 4 days ago Biotest's Yimmugo® Enters the U.S. Market Biotest AG U.S. Market Yimmugo® Launch Primary Immunodeficiencies Plasma-derived Medicines
PRESS RELEASE published on 10/09/2025 at 17:30, 1 month 4 days ago Biotest’s Yimmugo® launches in the United States Biotest AG launches Yimmugo®, a polyvalent human normal immunoglobulin (IVIg) for primary immunodeficiencies in the U.S., marking a significant milestone for the company's global growth strategy Biotest AG Yimmugo U.S. Launch Primary Immunodeficiencies IVIg
BRIEF published on 09/19/2025 at 15:05, 1 month 25 days ago Biotest AG Schedules Extraordinary General Meeting for Legal Form Change Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 09/19/2025 at 15:00, 1 month 25 days ago Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A. Biotest AG's extraordinary general meeting convened at the request of Grifols S.A. to discuss changing legal form to a partnership limited by shares (KGaA) on 28 October 2025 Extraordinary General Meeting Biotest AG Legal Form Change Grifols Partnership Limited By Shares
Published on 11/14/2025 at 15:00, 26 minutes ago Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians
Published on 11/14/2025 at 15:00, 26 minutes ago Vox Royalty Announces Appointment to Board of Directors
Published on 11/14/2025 at 15:00, 26 minutes ago Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
Published on 11/14/2025 at 15:00, 26 minutes ago Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 11/14/2025 at 14:30, 56 minutes ago Gladstone Investment Announces Intent to Redeem All Outstanding 8.00% Notes due 2028
Published on 11/14/2025 at 15:15, 10 minutes ago BingX Unveils Listing FastTrack for Swift and Transparent Token Onboarding
Published on 11/14/2025 at 13:30, 1 hour 56 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 11/14/2025 at 13:26, 1 hour 59 minutes ago Original-Research: Mister Spex SE (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 11/14/2025 at 13:10, 2 hours 15 minutes ago DeFi Technologies Inc. Announces Q3 2025 Financial Results: Revenues of $22.5 million, Operating Income of $9 million, and CEO Transition
Published on 11/13/2025 at 18:30, 20 hours 56 minutes ago RESULTS OF THE COMBINED GENERAL MEETING ON NOVEMBER 13, 2025
Published on 11/13/2025 at 17:45, 21 hours 41 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2025
Published on 11/13/2025 at 17:40, 21 hours 46 minutes ago Mersen selected by CATL to supply advanced fuses for battery systems
Published on 11/13/2025 at 17:40, 21 hours 46 minutes ago Financial information for the period ended 30 September 2025
